Current investments
 |
BONESUPPORT is a rapidly growing commercial stage orthobiologics company.The company develops and commercialises innovative injectable bioceramic bone graft substitutes to treat bone voids based on its novel, proprietary CERAMENT™ technology platform.
The marketed products CERAMENT™|BONE VOID FILLER (BVF), CERAMENT™|G and CERAMENT™ V target a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot. BONESUPPORT is headquartered in Lund, Sweden and listed on the Nasdaq Stockholm on 21 June 2017. |
 |
Bioservo is a technology and development company that has a leading global position within soft exoskeleton technology to support people in need of extra strength and endurance.The company’s key product is a glove which is based on the proprietary Robotic SEM™ Technology and is used for both rehabilitation within health and medical care and preventively for professionals in the industry.
Bioservo is headquartered in Stockholm, Sweden, and listed on the Nasdaq Stockholm on 22 May 2017. |
Realised investments
 |
Kibion is a global leader in complete solutions for rapid reliable Urea Breath Tests for diagnosing the stomach ulcer bacterium Helicobacter pylori.The company supplies test systems and high-quality instruments to institutions, hospitals and laboratories in more than 50 countries around the world.
Tellacq Partners acquired the company in April 2015 from the Swedish pharmaceutical company Orexo AB, with a focus on strengthening its operations and continuing its growth journey. Kibion was successfully divested in September 2016 to the French company Laboratoires Mayoly Spindler. |
Previous investments supported by members of the Tellacq Partners team include:
 |
Based in Zurich, Switzerland, Nycomed is a global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management, complemented by a range of OTC products.Nycomed was led by Håkan Björklund as CEO and Runar Bjørklund as CFO from 1999 to 2011. Under their leadership, Nycomed grew from a predominantly Scandinavian business into a global pharmaceutical company with leading market positions in Europe, Russia/CIS, Brazil and Latin America. Nycomed employed 12,500 people globally and sold products in more than 100 countries.
Nycomed was owned by a consortium of private equity funds including Nordic Capital, DLJ Merchant Banking Partners, Avista Capital Partners and Coller Capital. In May 2011, Takeda Pharmaceutical Company announced its acquisition of Nycomed for €9.6 billion. |
 |
Based in Uppsala, Sweden, Phadia develops, manufactures and markets complete blood-test systems to support the clinical diagnosis and monitoring of allergy and autoimmune diseases. Phadia is the global leader for in vitro allergy diagnostics and a European leader in autoimmunity diagnostics.Phadia was led by Magnus Lundberg as CEO and Anders Lundmark as CFO from 2005 to 2011. Under their leadership, Phadia expanded significantly through investment in sales force, new product launches and geographic expansion. Phadia employed approximately 1,500 people globally, with more than 5,000 systems installed in more than 3,000 laboratories worldwide.
Phadia was owned by Cinven, a leading international private equity fund. In June 2011, Thermo Fisher Scientific announced its acquisition of Phadia for €2.5 billion. |